Vital Access Corp. Announces First U.S. Commercial Implantation Of VWING Vascular Needle Guide
Vital Access today announced the first U.S. commercial implantation of their VWING Vascular Needle Guide, in a patient presenting with cannulation challenges and with difficulties in achieving ideal dialysis access due to the depth and tortuosity of their AV fistula.
The VWING Vascular Needle Guide was recently granted FDA market approval following completion of a multi-center, prospective clinical study. The VWING is a surgically placed vascular needle guide that is completely subcutaneous and extravascular. The VWING provides an easily palpable target for needle insertion and guides a dialysis needle directly to the targeted vessel, enabling the use of blunt needles via a guided constant site or "buttonhole" cannulation.
John R. Ross, M.D., who performed the implantation procedure, stated, "The VWING is an extraordinarily promising new technology for primary fistulae and for fistulas that require a revision to achieve cannulation. The VWING has many applications, including the potential to become the standard of care for access of deep fistulae."
"We are excited that the VWING is now available to and being used by U.S. patients," said Doug Smith, President and CEO of Vital Access. "Our company is committed to improving patient care. We believe that the VWING is a great step toward that goal, enabling access of many fistula locations, including challenging locations that would otherwise require invasive surgical revisions."